Top

International Journal of Clinical Oncology

Published in:

01-04-2017 | Original Article

A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with breast cancer

Authors: Ying Liu, Ying Liao, Linlin Xiang, Kuo Jiang, Siyao Li, Mingmei Huangfu, Shilong Sun

Published in: International Journal of Clinical Oncology | Issue 2/2017

Abstract

Background

Specific circulating autoantibodies are produced by host immune systems to respond to antigens that arise during tumorigenesis. To achieve auxiliary diagnosis, the present study was designed to test whether circulating autoantibodies against tumor-associated antigens (TAAs) were altered in early breast cancer.

Methods

A total of 102 breast cancer patients and 146 age-matched healthy volunteers were recruited to participate in this study. Autoantibody expression was tested using in-house developed enzyme-linked immunosorbent assay (ELISA) with linear peptide envelope antigens derived from TAAs.

Results

Student’s t tests showed that expression of autoantibodies against the panel (p16, c-myc, TP53, and ANXA-1) was significantly higher in the breast cancer group, stage I and II breast cancer group, and stage III and IV breast cancer group than in the healthy control group (p < 0.001, p < 0.001, p < 0.001). The sensitivities of detection of the panel (90% specificity) in these groups were 33.3%, 31.7%, and 33.3%, respectively, significantly higher than that of any single autoantibody.

Conclusion

The panel of autoantibodies is more sensitive than single TAA autoantibody detection and may be used as biomarkers for early diagnosis of breast cancer.

Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed

Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefPubMed

Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1748CrossRefPubMedPubMedCentral

Fuzery AK, Levin J, Chan MM et al (2013) Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 10(1):13CrossRefPubMedPubMedCentral

Keshaviah A, Dellapasqua S, Rotmensz N et al (2007) CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 18(4):701–708CrossRefPubMed

Kim HS, Park YH, Park MJ et al (2009) Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat 118(1):89–97CrossRefPubMed

Ali HQ, Mahdi NK, Al-Jowher MH (2013) The value of CA15-3 in diagnosis, prognosis and treatment response in women with breast cancer. J Pak Med Assoc 63(9):1138–1141PubMed

Shao Y, Sun X, He Y et al (2015) Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One 10(7):e0133830CrossRefPubMedPubMedCentral

Chapman C, Murray A, Chakrabarti J et al (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18(5):868–873CrossRefPubMed

10.

Tan HT, Low J, Lim SG et al (2009) Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276(23):6880–6904CrossRefPubMed

11.

Zuo X, Chen L, Liu L et al (2016) Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer. Tumor Biol 37(1):1309–1317CrossRef

12.

Chapman C, Murray A, Chakrabarti J et al (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18(5):868–873CrossRefPubMed

13.

Huangfu M, Xu S, Li S et al (2016) A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with cervical cancer. Tumor Biol 37(7):8709–8714CrossRef

14.

Xu S, Huangfu M, Jia X et al (2015) FOXP3 autoantibody as a potential early prognostic serum biomarker in patients with cervical cancer. Int J Clin Oncol 20(5):982–988CrossRefPubMed

15.

Zhang C, Ye L, Guan S et al (2014) Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer. Tumour Biol 35(3):2047–2051CrossRefPubMed

16.

Ye L, Guan S, Zhang C et al (2013) Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma. Tumour Biol 34(3):1873–1877CrossRefPubMed

17.

Guan S, Liu B, Zhang C et al (2013) Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma. Clin Transl Oncol 15(10):825–829CrossRefPubMed

18.

Chen C, Huang Y, Zhang C et al (2015) Circulating antibodies to p16 protein? derived peptides in breast cancer. Mol Clin Oncol 3(3):591–594PubMedPubMedCentral

19.

Baldwin RW (1955) Immunity to transplanted tumour: the effect of tumour extracts on the growth of homologous tumours in rats. Br J Cancer 9(4):646–651CrossRefPubMedPubMedCentral

20.

Graham JB, Graham RM (1955) Antibodies elicited by cancer in patients. Cancer (Phila) 8(2):409–416CrossRef

21.

Qiu J, Choi G, Li L et al (2008) Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 26(31):5060–5066CrossRefPubMedPubMedCentral

22.

Cunha LL, Morari EC, Nonogaki S et al (2012) Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics (Sao Paulo) 67(5):483–488CrossRef

23.

Farrell AS, Sears RC (2014) MYC degradation. Cold Spring Harb Perspect Med 4:a014365CrossRefPubMedPubMedCentral

24.

Ye L, Wang W, Chen C et al (2015) Study of circulating IgG antibodies to BIRC5 and MYC in non-small cell lung cancer. FEBS Open Bio 5:809–812CrossRefPubMedPubMedCentral

25.

Tornesello ML, Buonaguro L, Buonaguro FM (2013) Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review. Gynecol Oncol 128(3):442–448CrossRefPubMed

26.

Muller PA, Vousden KH (2014) Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25(3):305–317CrossRef

27.

Miller LD, Smeds J, George J et al (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102(38):13550–13555CrossRefPubMedPubMedCentral

28.

Xia J, Shi J, Wang P et al (2016) Tumor-associated autoantibodies as diagnostic biomarkers for breast cancer: a systematic review and meta-analysis. Scand J Immunol 83(6):393–408CrossRefPubMed

29.

Zhang Z, Huang L, Zhao W et al (2010) Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Res 70(6):2379–2388CrossRefPubMedPubMedCentral

30.

Shen D, Nooraie F, Elshimali Y et al (2006) Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Hum Pathol 37(12):1583–1591CrossRefPubMed

31.

Casiano CA, Mediavilla-Varela M, Tan EM (2006) Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics 5(10):1745–1759CrossRefPubMedPubMedCentral

32.

Desmetz C, Bascoul-Mollevi C, Rochaix P et al (2009) Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 15(14):4733–4741CrossRefPubMed

Title: A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with breast cancer
Authors: Ying Liu
Ying Liao
Linlin Xiang
Kuo Jiang
Siyao Li
Mingmei Huangfu
Shilong Sun
Publication date: 01-04-2017
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-1047-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2017

Recent progress and perspectives on prostate cancer biomarkers

Oncologic and obstetric outcomes and complications during pregnancy after fertility-sparing abdominal trachelectomy for cervical cancer: a retrospective review

Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma

Association between UGT1A1*28*28 genotype and lung cancer in the Japanese population

Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study

Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Association between UGT1A12828 genotype and lung cancer in the Japanese population